Specialty vaccine company PaxVax has acquired the oral typhoid vaccine Vivotif from Crucell, as well as its manufacturing facility in Thörishaus, Switzerland. Financial terms of the transaction were not disclosed.
Swiss-based Mymetics has agreed with Australian biotech Imugene to manufacture and develop its cancer immunotherapy HER-Vaxx, which is expected to enter into a Phase I/II clinical trial in 2015.
Oncology development company Celsion will acquire Egen, a biotech company that is developing nucleic acid-based therapeutics, for $14m upfront, with the chance for more than $30m in milestone payments.
The US Food and Drug Administration (FDA) has approved a second “Breakthrough Therapy” biologic but it is still unclear whether the programme speeds drugs to market, says an expert.
Cell therapy developer NeoStem has agreed to acquire California Stem Cell in a deal worth up to $124M, and includes CSC’s manufacturing facility in Irvine, CA.
Revising the regulations that govern gene and cell therapies - known as advanced therapy medicinal products (ATMPs) - will increase the number of marketing authorisation applications for such products and attract more Big Pharma involvement according...
CMO Cytovance Biologics is extending its manufacturing agreement with Precision Biologics to advance clinical trials with its leading monoclonal antibody candidate, which is being developed as a therapeutic candidate for pancreatic and colorectal cancers....
Synthetically engineered tracheas may be marketed sooner than previously thought as a Harvard Bioscience spinoff prepares to produce the “scaffolds” for growing tracheas in more clinical trials.
Biosimilar clinical trials are increasing but levels of physician oversight and regulatory decisions are still hurdles to overcome, say Parexel, PPD and Vince & Associates.
Big Pharma interest in antibody drug conjugates (ADC) hit another high this week with Roche ,Novartis and AstraZeneca each announcing investments that boost their ability to develop and manufacture these small-molecule monoclonal antibody (mAb) drug...
PharmAthene and Theraclone Sciences announced plans to merge and continue the joint development of monoclonal antibodies (mAbs) and vaccines on the verge of progressing to Phase II and III trials.
inVentiv Health and Oncobiologics are employing a unique risk-sharing partnership to bring a number of the biggest blockbuster biologics to market as biosimilars.
Piramal is upgrading its ADC (antibody drug conjugate) manufacturing capacity in response to demand from clients in late phase trials looking to ramp up production.
Stem cell therapeutics firm ReNeuron will conduct clinical development and – eventually – manufacturing at a new UK base in Wales in a move facilitated by Arthurian Life Sciences.
Early clinical research organisation Celerion has added a containment room to its UK facility in response to client demand for live biologics and vaccine studies.
Although preclinical work for CROs has fallen flat in recent quarters, Covance is looking to take advantage of the industry’s shift to early biologic developments and lead optimization.
Evotec says it is confident underlying growth, expansion of its clinical stage pipeline and upcoming milestone payments will counter Q1’s downcast results.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Catalent, Hospira and Eisai.
Eisai has tasked a new exec with making trials more likely to succeed just a few months after its candidate ovarian cancer blockbuster failed at Phase III.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Lonza and SynteractHCR.
The US FDA’s ability to inspect facilities, trial sites, and deal with all but its most pressing priorities will be restricted by mandatory government spending cuts according to the Alliance for a Stronger FDA.
Welcome to Outsourcing-Pharma.com’s round-up of CRO focused partnerships and collaborations including news from Particle Science and Agility Clinical Partners.
Biopharmaceutical CMOs have seen their business slowly shrink as companies seek less volume and smaller batches, but outsourcing is expected to increase over the next three years.
Quintiles painted a rosy picture of the CRO sector in its much anticipated IPO, predicting that biopharma R&D spending will increase and demand for outsourced research will grow.
The UK's cell therapy industry now has a database of all ongoing clinical trials in the country with the aim of expanding research partnerships and pushing more early-stage trials to later stages.
Catalent has upgraded its North Carolina, US, sterile development and analytics plant to increase its aseptic fill-finish activities four-fold in a bid to boost its integrated biologics offering.
in-PharmaTechnologist presents its weekly round-up of the latest climbers on the pharmaceutical career ladder, including news from Novasep, BioTime and Syndax.
Pharmas and biopharmas should adopt a “nimble”, more flexible approach when building relationships with CROs to stay ahead of the changing market, according to a new report.
Pierrel Research is close to inking a takeover deal with Swiss R&D firm monoBIOTECH that it says will help shape“the new paradigm of the drug discovery and development process.”
Celerion and Ricera Biosciences have launched a new joint venture to provide a cost-cutting one-stop-shop solution for companies developing and commercialising biosimilars.
Outsourcing-pharma.com presents a round up the latest developments in the contract manufacturing sector – with news from Cambrex, Florida Biologix, SCM Pharma, Recipharm and OctoPlus.
in-PharmaTechnologist presents its weekly round-up of the latest new faces at pharmas and biotechs, including news from Dicerna, Auxilium and Essentialis.
Chemicals supplier Lonza will manufacture the API for a candidate Alzheimer’s disease drug being developed by Elan in an agreement announced yesterday.
Catalent is to buy clinical trial supply assets from Aptuit for $410m (€285m) as it adds scale to handle the shift to preferred provider relationships.
BioMarin will buy Pfizer’s biologics manufacturing plant in Shanbally, Cork, Ireland to add production capacity for its candidate mucopolysaccharidosis treatment.